Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 6 January 2026 - 9 January 2026

Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

New York, Jan 9, 2026, 11:53 EST — Regular session Liquidia Corp shares jumped nearly 15% in morning trading on Friday after the drugmaker posted preliminary full-year figures for its newly launched pulmonary drug, easing near-term worries about demand and cash use. The move matters because Yutrepia is Liquidia’s main growth engine, and the stock has been trading like a…
9 January 2026
····
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

NEW YORK, Jan 9, 2026, 10:58 (EST) CICC initiated coverage on Novo Nordisk’s U.S.-listed American depositary receipt (ADR) — a U.S.-traded certificate that represents shares in a foreign company — with an outperform rating and a $73.50 price target, a Finwire report carried by MarketScreener showed on Friday. Novo’s Copenhagen-listed stock was up about 3%. (MarketScreener) The call lands as…
9 January 2026
···
Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

PARIS, Jan 8, 2026, 20:02 (CET) — Market closed Shares in French biotech Abivax SA (ABVX.PA) closed down 9.49% at 99.20 euros on Thursday, after swinging between 112.40 euros at the open and a low of 94.20 euros. The stock slipped back under the 100-euro mark, with volume at about 246,000 shares, after a 6% rise the day before. MarketScreener…
8 January 2026
····
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

New York, January 8, 2026, 13:12 ET — Regular session AbbVie Inc shares fell on Thursday after the drugmaker denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge that will dent its 2025 profit outlook. AbbVie stock (ABBV) was down 3.7% at $224.84 at 1:12 p.m. ET, after swinging between $231.93 and $223.84. The decline takes…
8 January 2026
····
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

New York, Jan 8, 2026, 08:36 EST — Premarket Eli Lilly shares were up 4.1% at $1,108.09 in premarket trade on Thursday after the drugmaker agreed to buy autoimmune-focused biotech Ventyx Biosciences for $1.2 billion in cash. The deal adds oral drugs for inflammatory diseases and a mid-stage program tied to a cardiovascular condition linked to obesity. “We like that…
8 January 2026
···
Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

New York, January 7, 2026, 20:54 (EST) — Market closed Bristol Myers Squibb shares rose 4.2% to $56.72 on Wednesday after UBS upgraded the drugmaker to buy and lifted its price target to $65 from $46. TipRanks The call matters now because big drugmakers are trying to convince investors they can bridge the next few years of patent losses without…
8 January 2026
····
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.” Why this matters now is simple: investors are testing whether Amgen’s…
8 January 2026
····
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. Reuters For AbbVie, a takeover would also sharpen its push to add new…
7 January 2026
··
Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

New York, Jan 7, 2026, 12:57 (EST) — Regular session Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE. The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity…
7 January 2026
···
Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

New York, January 7, 2026, 11:41 EST — Regular session. Eli Lilly and Company shares were up 3.3% at $1,099.44 in late morning trade, pushing back toward the $1,100 level as investors cheered fresh deal chatter around the drugmaker’s pipeline. (Reuters) The lift matters now because the market is watching how Lilly defends its growth run while competitors push pill…
7 January 2026
···
Liquidia stock slides after Needham swaps LQDA off its 2026 Conviction List

Liquidia stock slides after Needham swaps LQDA off its 2026 Conviction List

New York, Jan 6, 2026, 15:31 EST — Regular session Shares of Liquidia Corp (LQDA) fell 6.2% to $30.17 in afternoon trading on Tuesday after Needham removed the stock from its 2026 “Conviction List,” a report said. The shares hit a session low of $29.47, down from Monday’s close of $32.15. The decline stood out against a firmer biotech backdrop.…
6 January 2026
····
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

NEW YORK, Jan 6, 2026, 08:19 EST — Premarket Cyclerion Therapeutics Inc shares jumped about 46% to around $2.01 in premarket trading on Tuesday after the company announced an expanded strategic collaboration with Medsteer to advance its closed-loop anesthetic platform, CYC-126. Benzinga The move matters because Cyclerion is trying to pair an anesthetic-based approach with a device-and-software system that adjusts…
6 January 2026
····
1 2 3 4 … 10

Stock Market Today

  • Smith + Nephew Acquires Integrity Orthopaedics to Expand Shoulder Repair Portfolio
    January 19, 2026, 2:22 PM EST. Smith + Nephew (SNN) has acquired US-based Integrity Orthopaedics for $225 million upfront plus $225 million in milestone payments. This move strengthens SNN's Sports Medicine portfolio through the Tendon Seam system, a next-generation rotator cuff repair technology aimed at reducing high re-tear rates common in shoulder repair. The deal supports SNN's strategy of innovation and expands its addressable market in the $875 million US rotator cuff repair segment. Shares remained flat post-announcement but SNN's stock has gained 8% over six months versus a 7.1% industry decline. The acquisition is expected to enhance margins by 2028 and drive sustainable growth with integration into the existing shoulder product suite.
Go toTop